-

07:29:13 PM

ZSAN Stock News

ZSAN - Zosano Pharma Corp

11/29/21 9:45 PM

Nasdaq : ZSAN

Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 220,000 shares of Zosano’s common stock to a new employee as an inducement award.

RHEA-AI

neutral

11/17/21 8:00 AM

Nasdaq : ZSAN

covid-19

Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the successful formulation of a COVID-19 vaccine candidate, obtained from a vaccine developer, utilizing Zosano’s microneedle patch system.

RHEA-AI

very positive

11/10/21 4:10 PM

Nasdaq : ZSAN

earnings

Zosano Pharma Reports Third Quarter 2021 Financial Results

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2021, as well as business highlights. “This quarter we made significant progress

RHEA-AI

neutral

10/04/21 8:00 AM

Nasdaq : ZSAN

Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the company has been granted a Type C written response only meeting with the U.S. Food and Drug Administration (“FDA”) regarding the resubmission

RHEA-AI

neutral

09/02/21 4:30 PM

Nasdaq : ZSAN

conferences

Zosano Pharma to Present at the H.C. Wainwright Virtual Global Investment Conference

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Investment Conference

RHEA-AI

neutral

08/10/21 4:05 PM

Nasdaq : ZSAN

earnings

Zosano Pharma Reports Second Quarter 2021 Financial Results

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2021, as well as business highlights. “We are pleased to have initiated the healthy

RHEA-AI

neutral

07/20/21 8:30 AM

Nasdaq : ZSAN

Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No. 11,058,630 titled Method of

RHEA-AI

very positive

05/26/21 4:05 PM

Nasdaq : ZSAN

clinical trial

Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and Pain

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine”

RHEA-AI

neutral

05/25/21 4:05 PM

Nasdaq : ZSAN

management

Zosano Appoints Industry Veteran, Kathy McGee, to its Board of Directors

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee, an accomplished biopharmaceutical executive, to its board of directors. Ms. McGee brings experience from a broad

RHEA-AI

neutral

05/12/21 4:05 PM

Nasdaq : ZSAN

earnings

Zosano Pharma Reports First Quarter 2021 Financial Results

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021, as well as business highlights. “We have gained clarity from the FDA on the

RHEA-AI

neutral

ZSAN Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.zosanopharma.com
CeoSteven Lo
Security nameZosano Pharma Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees45
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address34790 Ardentech Ct
StateCalifornia
CityFremont
Zip94555-3657
CountryUS
Phone15107451200

ZSAN Description:

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.